Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	10.17M 8.88M 8.2M 7.56M 14.24M 979M 14.56M 97.99M 38.54M 479M 38.18M 37.34M 1.65B	P/E 2026 *	-0.47x	P/E 2027 *	-0.53x
Enterprise Value	10.17M 8.88M 8.2M 7.56M 14.24M 979M 14.56M 97.99M 38.54M 479M 38.18M 37.34M 1.65B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	94.62%	Yield 2026 *	-	Yield 2027 *	-

06-22	Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program	CI
06-22	Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program	MT
06-15	Top Premarket Decliners	MT
06-15	Ladenburg Thalmann Downgrades Traws Pharma to Neutral From Buy, Price Target is $3	MT
06-15	Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell	MT
06-12	Traws Pharma Provides Regulatory Update on Influenza Program	CI
05-27	Traws Pharma Advances Novel Broad-Spectrum Combination Antiviral Agent Targeting Hantavirus And Ebola Virus Disease Outbreaks	CI
05-22	Traws Pharma Inc files for offering of up to $3.1 million in common stock	RE
05-20	Hantavirus vaccines and treatments under development	RE
05-15	Traws Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-08	Traws Pharma Expands Antiviral Program to Target Hantavirus Infections; Shares Up Pre-Bell	MT
05-08	Traws Pharma to advance potential clinical candidates for the treatment of Hantavirus infections	RE
05-08	Traws Pharma, Inc. Advances Potential Clinical Candidates For The Treatment Of Hantavirus Infections	CI

06-15	Ladenburg Thalmann Downgrades Traws Pharma to Neutral From Buy, Price Target is $3	MT
12-03	HC Wainwright Initiates Traws Pharma at Buy With $8 Price Target	MT
23-04-21	HC Wainwright Upgrades Onconova Therapeutics to Buy From Neutral, Price Target is $11	MT
22-03-01	Ladenburg Thalmann Starts Onconova Therapeutics at Buy With $7 Price Target	MT
21-05-18	ONCONOVA THERAPEUTICS : Guggenheim Starts Onconova Therapeutics at Buy With $4 Price Target	MT

06-22	Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program	AQ
06-12	Traws Pharma Provides Regulatory Update on Influenza Program	AQ
05-27	Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks	AQ
05-15	Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results	AQ
05-11	Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections	AQ

04-14	HVIVO flambe grâce à un contrat
21-03-17	Aktien New York Schluss: Dow auf Rekordhoch - Geldpolitik bleibt locker
21-03-17	Aktien New York: Überwiegend Verluste kurz vor geldpolitischen Signalen der Fed
21-03-17	Aktien New York Ausblick: Zurückhaltung vor geldpolitischen Signale der Fed

Onconova Therapeutics Inc Stock Nasdaq

Stocks

US68232V1089

Biotechnology & Medical Research

Valuation: Onconova Therapeutics Inc

Latest news : Onconova Therapeutics Inc

Last Transcript: Onconova Therapeutics Inc

Analysts' recommendations: Onconova Therapeutics Inc

Press Releases: Onconova Therapeutics Inc

News in other languages: Onconova Therapeutics Inc

Quotes and Performance

Managers and Directors: Onconova Therapeutics Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
Iain Dukes CEO	Chief Executive Officer	67	2025-03-30
Charles Parker DFI	Director of Finance/CFO	45	2025-07-04
Robert Redfield CTO	Chief Tech/Sci/R&D Officer	74	2024-03-31

Director	Title	Age	Since
Jack Stover CHM	Chairman	73	2025-04-14
Mary Shoemaker BRD	Director/Board Member	65	2020-03-31
Trafford Clarke BRD	Director/Board Member	68	2022-12-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCONOVA THERAPEUTICS INC	-5.13%	+0.55%	-	-	10.17M
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+376.72%	+599.59%	39.58B
BEONE MEDICINES AG	-1.70%	+4.46%	+7.46%	+57.67%	34.69B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+26.35%	-6.83%	34.42B
CELLTRION, INC.	+0.06%	+0.34%	+2.32%	+29.30%	27.11B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+68.48%	+117.39%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+15.90%	+19.65%	14.05B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+15.74%	-30.62%	13.02B
ABIVAX	-0.08%	-3.01%	+1,271.69%	+649.69%	11.76B
Average	-0.34%	+0.04%	+223.08%	+179.48%	22.91B
Weighted average by Cap.	+0.24%	+0.36%	+171.43%	+187.42%

	2026 *	2027 *
Net sales	-	-
Net income	-21.3M -18.61M -17.18M -15.83M -29.84M -2.05B -30.5M -205M -80.75M -1B -79.99M -78.24M -3.46B	-24.25M -21.19M -19.56M -18.03M -33.97M -2.34B -34.73M -234M -91.93M -1.14B -91.07M -89.07M -3.94B
Net Debt	-	-